$18+ Bn Monoclonal Antibody Diagnostic Reagent Market - 13.5% CAGR by 2028, Globally - Rising Prevalence of Cancer and Chronic Diseases, Extensive R&D Efforts to Develop Novel Therapies, Presence of Strong Pipeline of Drugs Under Trial
October 03, 2022 06:55 ET
|
The Insight Partners
New York, Oct. 03, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on "Monoclonal Antibody Diagnostic Reagent Market Size, Share, Revenue, Growth Strategy, Industry...
Primary endpoint met in COMET-TAIL Phase 3 trial evaluating intramuscular administration of sotrovimab for early treatment of COVID-19
November 12, 2021 07:10 ET
|
Vir Biotechnology, Inc.
– COMET-TAIL Phase 3 data demonstrated that intramuscular administration of sotrovimab was non-inferior and offered similar efficacy to intravenous administration for high-risk populations – – The...
Vir Biotechnology Announces First Marketing Authorization for its First Commercial Product, Sotrovimab, Granted in Australia
August 23, 2021 08:30 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the first marketing authorization, granted in Australia, for its first commercial product,...
Vir Biotechnology Announces New Research Demonstrating Novel Mechanisms by Which SARS-CoV-2 Enters Host Cells
April 08, 2021 08:30 ET
|
Vir Biotechnology, Inc.
– Growing body of evidence suggests monoclonal antibodies that target a conserved epitope have the potential to be highly effective against SARS-CoV-2 and associated known mutations – – Newly...
Vir Biotechnology Announces New Preclinical Research Demonstrating VIR-7831 Maintains Neutralizing Activity Against the SARS-CoV-2 California Variant
April 05, 2021 08:00 ET
|
Vir Biotechnology, Inc.
– Data add to growing body of pre-clinical evidence demonstrating that VIR-7831 maintains activity against all known circulating variants of concern – – Plasma from vaccinated individuals and several...
Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19
March 29, 2021 08:30 ET
|
Vir Biotechnology, Inc.
INDIANAPOLIS and SAN FRANCISCO and LONDON, March 29, 2021 (GLOBE NEWSWIRE) -- Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today...
GSK and Vir Biotechnology Announce Submission of Emergency Use Authorization Request to FDA for VIR-7831 for the Early Treatment of COVID-19
March 26, 2021 08:30 ET
|
Vir Biotechnology, Inc.
LONDON and SAN FRANCISCO, March 26, 2021 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the submission of an application to the...
Vir Biotechnology and GSK Announce VIR-7831 Reduces Hospitalization and Risk of Death in Early Treatment of Adults with COVID-19
March 10, 2021 20:22 ET
|
Vir Biotechnology, Inc.
– Independent Data Monitoring Committee recommends stopping Phase 3 COMET-ICE trial early given an 85% reduction in hospitalization or death – – Vir and GSK plan to immediately seek Emergency Use...
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
February 25, 2021 16:01 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended...
Vir Biotechnology Announces New Data Highlighting the Importance of Targeting Conserved Regions of the SARS-CoV-2 Spike Protein in the Development of Therapeutics
February 01, 2021 08:00 ET
|
Vir Biotechnology, Inc.
– Scientists continuing to advance critical research on mechanisms of immune evasion exemplified by emerging SARS-CoV-2 variants – – Study identifies the N-terminal domain of the SARS-CoV-2 spike...